#USA #oncology #biotechnology #Shelton #Intensity

Intensity Therapeutics Secures $6.6 Million from Stock Sales

In a recent financial development, Intensity Therapeutics, Inc. (Nasdaq: INTS), a notable player in the late-stage clinical biotechnology industry, has successfully raised $6.6 million from its At-the-Market (ATM) stock sales program in July 2025. This funding initiative came alongside the company’s efforts to advance its innovative intratumoral cancer therapies aimed at treating hard-to-kill tumors and enhancing immune responses against cancer cells.

A Sign of Growth and Stability

The company sold a total of 19,868,658 shares at an average price of $0.3323 per share as part of this program, providing $6.3 million in net proceeds. This strategic move not only strengthens Intensity's financial position but also extends its cash runway into the second half of 2026, significantly boosting investor confidence and allowing for continued progress in their clinical trial programs.

Lewis H. Bender, President and CEO of Intensity Therapeutics, commented on the development, expressing satisfaction with the favorable market conditions: "We managed to capitalize on strong liquidity and attractive stock prices. The profits from these ATM sales will considerably enhance our balance sheet and enable us to push forward with our clinical trials well into 2026." He further stated that the average stock price achieved exceeded expectations, being over 10% higher than that of the recent public offering conducted in June 2025, while also noting that the costs to obtain this new capital were significantly lower.

Understanding At-the-Market Offerings

At-the-Market (ATM) offerings are a strategic fundraising method allowing public companies to sell newly issued shares directly to the market at prevailing prices rather than going through a traditional underwritten offering. This technique provides companies the flexibility to raise necessary funds incrementally and opportunistically, minimizing market disruption and associated costs.

INT230-6: The Lead Product Candidate

Enhancing their clinical endeavors, INT230-6 stands as Intensity's flagship investigational candidate, designated for direct intratumoral injections. Developed through the company’s proprietary DfuseRx℠ technology, INT230-6 incorporates a dual formulation containing the well-established anti-cancer agents cisplatin and vinblastine sulfate, alongside a SHAO molecule that improves the dispersion of these potent drugs within the tumor environment. This innovative approach allows INT230-6 not only to combat tumors directly but also to engage the immune system against cancer, achieving results without the common immune suppression linked to systemic chemotherapy.

Clinical Trials and Future Directions

Intensity Therapeutics shows promise with ongoing and completed clinical trials, including a Phase 1/2 study in metastatic cancers, such as sarcomas, plus the INVINCIBLE-2 Study, which targets locally advanced breast cancer patients who have not undergone chemotherapy prior to surgery. Current developments also include a Phase 3 trial for soft tissue sarcoma, designed to evaluate INT230-6’s efficacy against standard care, and a collaborative Phase 2 study with the Swiss Cancer Group focusing on patients with presurgical triple-negative breast cancer.

For more details regarding Intensity Therapeutics, including their research and advancements in cancer therapeutics, interested parties can visit their official website at www.intensitytherapeutics.com.

Conclusion

With the accumulation of substantial capital from its recent ATM stock sales, Intensity Therapeutics is poised to advance its innovative cancer treatment programs, showing potential to redefine the treatment landscape for various malignancies that traditionally resist standard therapies. As they continue to explore the capabilities of INT230-6, the company is taking significant steps toward potentially turning aggressive cancers into manageable conditions through novel treatment methodologies.